Lab of Translational Medicine, Gachon University Lee Gil Ya Cancer and Diabetes Institute, Incheon, Korea.
J Dig Dis. 2011 Apr;12(2):71-81. doi: 10.1111/j.1751-2980.2011.00482.x.
Heat shock proteins (HSPs) are crucial for the maintenance of cellular integrity during normal cell growth as well as pathophysiological conditions. While acting as molecular chaperones with their folding activities, HSPs play a cytoprotective role to rescue epithelial cells from several gastric damages including non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori. Since the exact relationship between HSP27 phosphorylation and biological function remains unknown in NSAID-induced gastropathy, we hypothesized that revaprazan, a novel acid pump antagonist, can secure significant cytoprotection from NSAID damages through HSP27 accentuation.
We evaluated protective actions of revaprazan against either in vivo animal model of indomethacin induced gastropathy or in vitro cell model focused on HSP27 expression and activation.
Indomethacin induced significant cytotoxicities accompanied with phosphorylated HSP27 and attenuated levels of HSP27 in the in vitro cell experiment and revaprazan administration protected stomach from indomethacin-induced gastric damages in accordance with HSP27 dephosphorylation in the in vivo animal experiment. HSP27 siRNA abolished these cytoprotective privileges of revaprazan. Indomethacin, 40 mg/kg, po, administration provoked significant levels of gastric damages accompanied with decrement in HSP27, while rats administrated with revaprazan prior to indomethacin imposed the accentuation of HSP27, of which levels were significantly correlated with the prevention of the indomethacin-induced gastric damages.
HSP27 phosphorylation with resultant decrease in HSP27 level was one of the mechanisms of indomethacin-induced cytotoxicity, of which post-translational modifications were prevented with revaprazan administration in the presence of indomethacin. Therefore, acid pump antagonist could be a choice for the prevention of NSAID-induced gastropathy backed up with distinctive cytoprotective action beyond acid suppressor.
热休克蛋白(HSPs)在正常细胞生长以及病理生理条件下对维持细胞完整性至关重要。HSPs 作为具有折叠活性的分子伴侣,发挥细胞保护作用,使上皮细胞免受包括非甾体抗炎药(NSAIDs)和幽门螺杆菌在内的多种胃损伤的影响。由于 HSP27 磷酸化与 NSAID 诱导的胃病中的生物学功能之间的确切关系尚不清楚,我们假设新型酸泵拮抗剂 revaprazan 可以通过强调 HSP27 来确保从 NSAID 损伤中获得显著的细胞保护作用。
我们评估了 revaprazan 对吲哚美辛诱导的胃病体内动物模型或专注于 HSP27 表达和激活的体外细胞模型的保护作用。
吲哚美辛在体外细胞实验中引起明显的细胞毒性,伴有磷酸化 HSP27 和 HSP27 水平降低,而 revaprazan 给药可根据体内动物实验中 HSP27 去磷酸化来保护胃免受吲哚美辛诱导的胃损伤。HSP27 siRNA 消除了 revaprazan 的这些细胞保护特权。吲哚美辛,40mg/kg,po,给药引起明显的胃损伤,伴有 HSP27 减少,而在吲哚美辛之前给予 revaprazan 的大鼠则增强了 HSP27,其水平与预防吲哚美辛诱导的胃损伤显著相关。
HSP27 磷酸化导致 HSP27 水平降低是吲哚美辛诱导细胞毒性的机制之一,在吲哚美辛存在的情况下,通过 revaprazan 给药可以防止其翻译后修饰。因此,酸泵拮抗剂可能是预防 NSAID 诱导的胃病的选择,其具有独特的细胞保护作用,超越了酸抑制剂。